Literature DB >> 3135171

Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 gram-negative clinical isolates.

G Piédrola1, I Galan, A Leyva, M C Maroto.   

Abstract

The antimicrobial activity of cefotaxime and its intermediate metabolite, desacetylcefotaxime, against 320 Gram-negative bacterial strains was analysed to investigate whether combination of the 2 substances led to increased bactericidal activity. The in vitro study of the minimum inhibitory concentration (MIC) showed the combination to be more effective against Escherichia coli, Klebsiella spp., Enterobacter spp. and Proteus mirabilis, requiring less than or equal to 50% of the concentration of cefotaxime alone to inhibit 90% of strains. For other micro-organisms the MIC90 for the combination was equal to or within 1 dilution of that for cefotaxime alone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135171     DOI: 10.2165/00003495-198800352-00014

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  9 in total

1.  Metabolism of cefotaxime in animals and man.

Authors:  J Chamberlain; J D Coombes; D Dell; J M Fromson; R J Ings; C M Macdonald; J McEwen
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

2.  Human metabolism of cefotaxime.

Authors:  D S Reeves; L O White; H A Holt; D Bahari; M J Bywater; R P Bax
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

3.  Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.

Authors:  N X Chin; H C Neu
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

4.  In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.

Authors:  K E Aldridge; C V Sanders; R L Marier
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

5.  Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

6.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

Review 7.  Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.

Authors:  R N Jones; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

8.  The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability.

Authors:  M Limbert; G Seibert; E Schrinner
Journal:  Infection       Date:  1982       Impact factor: 3.553

9.  Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

Authors:  R Wise; P J Wills; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

  9 in total
  2 in total

1.  Pharmacokinetics of cefotaxime and desacetylcefotaxime in patients with liver disease.

Authors:  R J Ko; F R Sattler; S Nichols; E Akriviadis; B Runyon; M Appleman; J L Cohen; R T Koda
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 2.  Determination and Identification of Antibiotic Drugs and Bacterial Strains in Biological Samples.

Authors:  Katarzyna Pauter; Małgorzata Szultka-Młyńska; Bogusław Buszewski
Journal:  Molecules       Date:  2020-05-31       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.